Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Nivolumab

5

XII.c Pericardial effusion (w/wo tamponade)

1
Last update : 25/08/2016
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
Avelumab
1
Durvalumab
3
Immune checkpoint inhibitors (ICI) - ICI combinatorial Rx
5
Lambrolizumab
4
PD-1/PD-L1-inhibitors or blocking agents/drugs
5
Pembrolizumab
5

Publications

Immune-mediated Pericarditis With Pericardial Tamponade During Nivolumab Therapy.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2018 Sep;41;329-331 2018 Sep
Recurrent Pericardial Effusion While Receiving Nivolumab for Metastatic Lung Adenocarcinoma: Case Report and Review of the Literature.
Clinical lung cancer 2018 Sep;19;e717-e720 2018 Sep
Nivolumab-Induced Pericardial Tamponade: A Case Report and Discussion.
Cardiology 2017;136;49-51 2017
Pericardial effusion with tamponade physiology induced by nivolumab.
International journal of cardiology 2016 Nov 01;222;613-614 2016 Nov 01

Powered by

  • ^
  • Contact
  • Cookies
  • About

The Pneumotox website uses cookies. By accessing or using our website, you consent to the collection, use and disclosure of the garnered information in accordance with our privacy policy.

Learn more about cookies